Lexicon Genetics Initiates Phase 1 Clinical Trial Of LX6171 For Cognitive Disorders

Lexicon Genetics Initiates Phase 1 Clinical Trial Of LX6171 For Cognitive Disorders: "Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has initiated a Phase 1 clinical trial for LX6171, a novel, orally administered small molecule compound for cognitive disorders. The trial initiation follows the clearance in July of Lexicon's Clinical Trial Authorization (CTA) filing for LX6171 by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). "